Patharapankal, Elizabeth J., Ajiboye, Adejumoke Lara, Mattern, Claudia, Trivedi, Vivek (2023) Nose-to-Brain (N2B) Delivery: An Alternative Route for the Delivery of Biologics in the Management and Treatment of Central Nervous System Disorders. Pharmaceutics, 16 (1). Article Number 66. ISSN 1999-4923. (doi:10.3390/pharmaceutics16010066) (KAR id:104562)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/1MB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.3390/pharmaceutics16010066 |
Abstract
In recent years, there have been a growing number of small and large molecules that could be used to treat diseases of the central nervous system (CNS). Nose-to-brain delivery can be a potential option for the direct transport of molecules from the nasal cavity to different brain areas. This review aims to provide a compilation of current approaches regarding drug delivery to the CNS via the nose, with a focus on biologics. The review also includes a discussion on the key benefits of nasal delivery as a promising alternative route for drug administration and the involved pathways or mechanisms. This article reviews how the application of various auxiliary agents, such as permeation enhancers, mucolytics, in situ gelling/mucoadhesive agents, enzyme inhibitors, and polymeric and lipid-based systems, can promote the delivery of large molecules in the CNS. The article also includes a discussion on the current state of intranasal formulation development and summarizes the biologics currently in clinical trials. It was noted that significant progress has been made in this field, and these are currently being applied to successfully transport large molecules to the CNS via the nose. However, a deep mechanistic understanding of this route, along with the intimate knowledge of various excipients and their interactions with the drug and nasal physiology, is still necessary to bring us one step closer to developing effective formulations for nasal–brain drug delivery.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.3390/pharmaceutics16010066 |
Uncontrolled keywords: | nose-to-brain, nasal delivery, CNS disorders, biologics |
Subjects: | R Medicine |
Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
Funders: | University of Kent (https://ror.org/00xkeyj56) |
SWORD Depositor: | JISC Publications Router |
Depositing User: | JISC Publications Router |
Date Deposited: | 10 Jan 2024 14:58 UTC |
Last Modified: | 05 Nov 2024 13:10 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/104562 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):